These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11823963)

  • 1. The role of cefoperazone-sulbactam for treatment of severe melioidosis.
    Apisarnthanarak A; Little JR
    Clin Infect Dis; 2002 Mar; 34(5):721-3. PubMed ID: 11823963
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.
    Thamprajamchit S; Chetchotisakd P; Thinkhamrop B
    J Med Assoc Thai; 1998 Apr; 81(4):265-71. PubMed ID: 9623020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis.
    Chetchotisakd P; Porramatikul S; Mootsikapun P; Anunnatsiri S; Thinkhamrop B
    Clin Infect Dis; 2001 Jul; 33(1):29-34. PubMed ID: 11389491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting.
    Kochhar P; Suvarna V; Duttagupta S; Sarkar S
    Value Health; 2008 Mar; 11 Suppl 1():S33-8. PubMed ID: 18387065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
    Borja J; Herreras A
    Clin Infect Dis; 1999 Feb; 28(2):406-7. PubMed ID: 10064264
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
    Beketov AS; Sidorenko SV; Pisarev VV; Komarov RM
    Antibiot Khimioter; 2003; 48(3):34-41. PubMed ID: 12914120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy between ceftriaxone and cefoperazone plus sulbactam in peri-operative treatment of acute suppurative cholangitis].
    Zhou XS; Zou SQ; Dong JH; Wu WZ; Zhang YD; Zhang TL; Zeng Z; Li NF; Man GT
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1879-82. PubMed ID: 15631798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro susceptibility of Burkholderia pseudomallei to cefoperazone-sulbactam combination.
    Koay AS; Rohani MY; Cheong YM
    Med J Malaysia; 1997 Jun; 52(2):158-60. PubMed ID: 10968074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin.
    Apisarnthanarak A; Mundy LM
    Int J Infect Dis; 2007 May; 11(3):283-4. PubMed ID: 16876452
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of cefoperazone/sulbactam in neonates.
    Ovali F; Gursoy T; Sari I; Divrikli D; Aktas A
    Pediatr Int; 2012 Feb; 54(1):60-3. PubMed ID: 21883691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effects of cefepime and sulbactam/cefoperazone on moderate and severe respiratory tract infection in children].
    Huang JJ; Zeng Q; Yu JL
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Sep; 25(9):1199-200. PubMed ID: 16174597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
    Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
    Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefoperazone or cefoperazone-sulbactam as perioperative antibiotic prophylaxis in transurethral surgery.
    Nielsen KT; Madsen PO
    J Chemother; 1989 Jul; 1(4 Suppl):1010-1. PubMed ID: 16312747
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
    Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
    Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The empirical antibiotic therapy of patients with acute leukemias: the results of a multicenter study].
    Kliasova GA; Savchenko VG; Parovichnikova EN; Isaev VG; Tolkacheva TV; Rossiev VA; Filatov LB; Tumakov VA; Iarikova EN; Rekhtman GB; Pristupa AS; Medvedeva NV; Sharov LN; Klimko NN; Porokhona ON; Lapin VA; Kaporskaia TS; Kaletin GI
    Ter Arkh; 1998; 70(7):15-21. PubMed ID: 9742629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and pharmacoeconomic perspective use of amoxicillin/sulbactam in the treatment of extra-hospital pneumonia].
    Sinopal'nikov AI; Zaĭtsev AA
    Voen Med Zh; 2006 Nov; 327(11):42-5. PubMed ID: 17300060
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cefoperazone (Medocef*) in the modern therapy of severe bacterial infections].
    Fomina IP; Smirnova LB
    Antibiot Khimioter; 2001; 46(10):35-41. PubMed ID: 11881192
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in the treatment of severe melioidosis.
    Chaowagul W
    Acta Trop; 2000 Feb; 74(2-3):133-7. PubMed ID: 10674641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition.
    Gasser R; Reisinger E; Eber B; Pokan R; Seinost G; Berglöff J; Horwarth R; Sedaj B; Klein W
    Microb Drug Resist; 1995; 1(4):341-4. PubMed ID: 9158807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modern possibilities of hepacef combi (cefoperazon/sulbactam) application for the treatment of surgical infection].
    Herych ID; Vashchuk VV
    Klin Khir; 2011 Feb; (2):65-9. PubMed ID: 21548334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.